Pathophysiological Basis
- Duchenne Muscular Dystrophy (DMD) is an X-linked recessive disorder caused by out-of-frame deletions (60–70%), duplications (5–10%), or nonsense/point mutations in the DMD gene on chromosome Xp21.
- Complete absence of the cytoskeletal protein dystrophin disrupts the dystrophin-glycoprotein complex (DGC) linking the intracellular actin cytoskeleton to the extracellular matrix.
- Sarcolemmal micro-tears during muscle contraction trigger massive calcium influx, calpain activation, chronic myofiber necrosis, chronic inflammation, and progressive replacement of muscle by fibrofatty connective tissue.
- Disease-modifying therapies (DMTs) aim to restore truncated or full-length dystrophin, skip mutated exons, bypass premature stop codons, or block downstream fibrosis and muscle degeneration.
1. Glucocorticoids And Dissociative Steroids
Standard Glucocorticoids
- Prednisolone ($0.75\text{ mg/kg/day}$) or Deflazacort ($0.9\text{ mg/kg/day}$) remains foundational standard care for all DMD patients aged $\ge 4$ years.
- Mechanism: Inhibits NF-$\kappa$B-mediated inflammation, reduces cytotoxic T-cell infiltration, and up-regulates utrophin; prolongs independent ambulation by 2 to 3 years.
- Adverse effects: Growth stunting, cushingoid habitus, osteoporosis, vertebral compression fractures, cataracts, and behavioral changes.
Vamorolone (Agamree) - Dissociative Steroid
- First-in-class "dissociative" synthetic steroid approved for DMD patients aged $\ge 2$ years.
- Mechanism: Retains anti-inflammatory transrepression (binding the glucocorticoid receptor and inhibiting NF-$\kappa$B), but does not activate transactivation (which drives classic steroid-response element gene transcription responsible for adverse metabolic events).
- Dose: $6\text{ mg/kg/day}$ orally once daily with a meal (maximum 300 mg/day).
- Clinical Advantage: Preserves motor function equivalent to standard corticosteroids while significantly mitigating growth deceleration, bone mineral density loss, and metabolic toxicity.
2. Micro-Dystrophin Gene Therapy: Elevidys
- Agent: Delandistrogene moxeparvovec-rokl (Elevidys).
- Vector Mechanism: Non-replicating recombinant Adeno-Associated Virus serotype rh74 (AAVrh74) delivering an engineered micro-dystrophin transgene containing critical rod domains and the cysteine-rich domain driven by a muscle-specific promoter (MHCK7).
- Administered as a single intravenous infusion ($1.33 \times 10^{14}\text{ vector genomes/kg}$).
2024–2025 FDA Label Expansion And Indications
- In June 2024, the FDA expanded approval to include both ambulatory and non-ambulatory DMD patients aged $\ge 4$ years with a confirmed mutation in the DMD gene.
- Full traditional approval was granted for ambulatory patients, and accelerated approval for non-ambulatory patients based on robust micro-dystrophin protein expression.
Critical Contraindications And Safety Boxed Warnings
- Absolute Contraindication: Any deletion in exon 8 and/or exon 9 in the DMD gene. Patients with these deletions develop severe, life-threatening immune-mediated myositis and cross-reactive T-cell responses against the recombinant micro-dystrophin transgene.
- Acute Serious Liver Injury: Immune-mediated hepatitis; mandates weekly liver function tests for the first 3 months and high-dose corticosteroid coverage (oral prednisolone $1\text{ mg/kg/day}$ initiated 1 day before infusion and continued for at least 60 days).
- Immune-Mediated Myocarditis: Monitor baseline troponin-I and ECG; repeat troponin-I weekly for the first month post-infusion.
- AAVrh74 Antibody Titers: Anti-AAVrh74 antibody titers must be $\le 1:400$ prior to infusion.
3. Downstream Fibrosis Inhibitor: Givinostat (Duvyzat)
- First oral non-steroidal Histone Deacetylase (HDAC) inhibitor approved for all DMD genetic variants in patients aged $\ge 6$ years.
- Pathophysiological Target: In dystrophic muscle, aberrant intracellular calcium hyper-activates HDACs, silencing muscle regenerative genes and promoting fibrofatty replacement.
- Givinostat inhibits HDACs, reducing muscle inflammation, blocking fibrofatty scar tissue accumulation, and promoting muscle fiber regeneration.
- Dosing: Weight-tiered twice-daily oral suspension taken with food.
- Monitoring Requirements:
- Baseline complete blood counts: Risk of dose-dependent thrombocytopenia and leukopenia (monitor platelets and ANC every 2–4 weeks initially).
- Fasting serum triglycerides (risk of hypertriglyceridemia).
- Periodic baseline and follow-up ECG to monitor for QTc prolongation.
4. Mutation-Specific Genetic Therapies
A. Antisense Oligonucleotides (Exon Skipping)
- Synthetic phosphorodiamidate morpholino oligomers (PMOs) that bind to pre-mRNA during splicing, masking targeted exons and restoring the open reading frame.
- Converts a severe out-of-frame DMD mutation into an in-frame, milder Becker-like dystrophin protein.
- Delivered as weekly intravenous infusions.
| Drug | Target Exon | Target Patient Population | Mechanism |
|---|---|---|---|
| Eteplirsen (Exondys 51) | Exon 51 | Amenable to exon 51 skipping ($\approx 13\text{–}14\%$ of DMD) | Skips exon 51 to restore reading frame |
| Golodirsen (Vyondys 53) | Exon 53 | Amenable to exon 53 skipping ($\approx 8\text{–}10\%$ of DMD) | Skips exon 53 to restore reading frame |
| Viltolarsen (Viltepso) | Exon 53 | Amenable to exon 53 skipping ($\approx 8\text{–}10\%$ of DMD) | Higher micro-dystrophin expression levels |
| Casimersen (Amondys 45) | Exon 45 | Amenable to exon 45 skipping ($\approx 8\%$ of DMD) | Skips exon 45 to restore reading frame |
B. Nonsense Mutation Read-Through (Ataluren)
- Ataluren (Translarna): Oral small molecule indicated for DMD caused by nonsense mutations (premature stop codons: UAA, UAG, UGA), accounting for 10% to 15% of cases.
- Enables ribosomes to read through premature stop codons, allowing translation of full-length functional dystrophin. Taken orally 3 times daily.
Comparative Overview Of DMD Disease-Modifying Therapies
| Modality / Drug | Target DMD Population | Primary Mechanism Of Action | Key Adverse Events / Monitoring |
|---|---|---|---|
| Vamorolone | All patients $\ge 2$ years | Dissociative steroid: transrepression without transactivation | Adrenal suppression on withdrawal; lower bone/growth toxicity |
| Givinostat | All patients $\ge 6$ years | Oral pan-HDAC inhibitor blocking muscle fibrofatty substitution | Thrombocytopenia, hypertriglyceridemia, QTc prolongation |
| Elevidys | Ambulatory & non-ambulatory $\ge 4$ years | AAVrh74-mediated micro-dystrophin gene transfer | Acute liver injury, troponin-I elevation, immune myositis |
| Exon-Skipping ASOs | Specific exon deletions (51, 53, 45) | PMO-mediated pre-mRNA splicing frame restoration | Renal tubular toxicity, proteinuria, requires weekly IV lines |
| Ataluren | Nonsense mutations only | Ribosomal read-through of premature termination codons | Gastrointestinal upset, elevated transaminases, dyslipidemia |